Objective-Therapeutic strategies to raise low plasma HDL-cholesterol levels, with concomitant normalization of the intravascular metabolism, physicochemical properties, and antiatherogenic function of HDL particles, are a major focus in atherosclerosis prevention. Methods and Results-Patients displaying Type IIB hyperlipidemia (nϭ14) and healthy controls (nϭ11) were recruited.
S ubstantial evidence from prospective epidemiological studies attests to the cardioprotective role of elevated levels of HDL-cholesterol. 1 The reverse cholesterol transport (RCT) pathway is frequently cited as the primary mechanism by which HDL protects against atherosclerosis and by which it may induce plaque regression. 2 The atheroprotective nature of HDL particles reflects a composite of multiple mechanisms. 3 In particular, HDL particles are intimately involved in the centripetal movement of free cholesterol from peripheral tissues, including the vessel wall, to the liver for its excretion, transformation or recycling. 4 The antiatherogenic properties of HDL can however be compromised in metabolic diseases associated with elevated cardiovascular risk. 5 Type IIB hyperlipidemia is a characteristic feature of metabolic diseases including type 2 diabetes and metabolic syndrome, and is frequently associated with premature atherosclerosis. Furthermore, Type IIB hyperlipid-emia is characterized by an imbalance between excess circulating levels of proatherogenic apoB-lipoproteins in the form of VLDL, VLDL-remnants, and LDL, among which VLDL-1 and small dense LDL predominate, relative to subnormal levels of antiatherogenic apoAI-lipoproteins. 5, 6, 7 In atherogenic dyslipidemias involving a low HDL phenotype associated with a moderate or marked degree of hypertriglyceridemia, HDL particles typically display pronounced structural, compositional, and functional alterations. 1, 5 Indeed, enrichment of HDL particles in triglyceride at the expense of cholesteryl ester is the most frequent abnormality in HDL lipid composition, and results directly from concomitant elevation in circulating levels of triglyceride-rich lipoproteins and in CETP activity. 7, 8 Accelerated plasma apoAI clearance and shedding of ApoAI from TG-rich HDL particles after lipolysis by hepatic lipase contribute to attenuated HDL particle stability, with reduction in plasma residence time, and concomitantly in HDL-C and apoAI levels. 9 In addition, modification of the core lipid content of HDL particles as a result of CETP-mediated CE-TG heteroexchange alters the conformation of ApoAI domains that are critical for HDL to act as lipid acceptors 10, 11 ; equally, such modification impairs the capacity of TG-enriched HDL particles to deliver CE to the liver through the SR-BI pathway. 12 Therapeutic strategies based on raising plasma HDL levels with concomitant normalization of their intravascular metabolism, physicochemical properties, and function, have become a major focus of research for the treatment of atherosclerosis and CVD. 4, 13 At present, CETP inhibitors represent the pharmacological strategy of greatest efficacy for elevation of plasma HDL-C levels in both fasting and postprandial states. 14, 15 The indirect reverse cholesterol transport pathway, involving CETP-mediated transfer of CE from HDL to VLDL, IDL, and LDL, predominates quantitatively as the major mechanism for return of CE from peripheral tissues to the liver in human plasma. 16 Pharmacological inhibition of CETP might therefore disrupt this pathway and might theoretically impair cholesterol flux from peripheral tissues to the liver. Inhibitors of CETP do not, however, alter fecal excretion of cholesterol in human subjects, 17 thereby suggesting that any potential reduction in cholesterol flux through the indirect pathway might be counterbalanced by acceleration of cholesterol transport through the direct RCT pathway. Consistent with this hypothesis, torcetrapib therapy preferentially generates large CE-rich HDL particles which efficiently promote cholesterol efflux from macrophages through the ABCG1-dependent pathway. 18 Large HDL particles have equally been shown to efficiently efflux cellular cholesterol via the SR-BI pathway, 19 thereby suggesting that SR-BImediated cholesterol efflux might also be enhanced after CETP inhibition.
CETP inhibitors are of potential relevance to the therapeutic normalization of defects in both the quantitative and qualitative characteristics of HDL in common dyslipidemic phenotypes associated with premature atherosclerosis such as Type IIB hyperlipidemia. We therefore evaluated the impact of torcetrapib on the physicochemical and functional properties of HDL and its major subfractions, HDL2 and HDL3, in Type IIB hyperlipidemia. These studies have revealed that CETP inhibition significantly reduced the CE donor activity of HDL2 from type IIB patients to subnormal levels; by contrast, absolute CE transfer rates from HDL3 were normalized. Torcetrapib-mediated inhibition of CETP significantly enhanced the capacity of HDL2 particles from dyslipidemic patients to mediate cellular free cholesterol efflux via both SR-BI and ABCG1 pathways. Finally, torcetrapib-mediated CETP inhibition was associated with an enhanced capacity of HDL particles to mediate selective hepatic uptake of CE.
Methods

Subjects and Blood Samples
Fourteen males aged between 36 and 59 years (mean: 46Ϯ7 years) displaying a combined hyperlipidemia typical of the Type IIB lipid phenotype (fasting plasma levels of total cholesterol Ն230 mg/dL, triglycerides Ն150 mg/dL, and apolipoprotein B Ն140 mg/dL), and 11 healthy nondyslipidemic male volunteers aged between 27 and 62 years (mean: 42Ϯ5 years) were selected for the study (supplemental Table I , available online at http://atvb.ahajournals.org). Patients were excluded if they displayed dysbetalipoproteinemia, diabetes mellitus, secondary causes of hyperlipidemia such as uncontrolled hypothyroidism, renal impairment or nephrotic syndrome, or known liver or muscle disease. Other exclusion criteria included uncontrolled hypertension, or a history of a major cardiovascular event. Type IIB patients and normolipidemic control subjects were nonobese and were matched for body mass index.
Dyslipidemic patients had ceased taking lipid-lowering drugs and stabilized their diet (AHA Step one diet or equivalent) over a 6-week period immediately before entering into the study. At week 0, a 6-week period of active treatment with atorvastatin only at 10 mg/d was initiated, followed by a 6-week period of active combination torcetrapib/atorvastatin therapy (60/10 mg/d).
Blood samples were obtained after an overnight fast at baseline (before treatment), after 6 weeks of atorvastatin alone (A) and after 6 weeks of torcetrapib/atorvastatin treatment (T/A). Blood was collected by venipuncture from the antecubital vein into sterile EDTA-containing tubes (final concentration of EDTA, 1 mg/mL), and plasma separated immediately by low-speed centrifugation (2500 rpm) for 20 minutes at 4°C and stored at Ϫ80°C until use.
The study was performed in accordance with the ethical principles set forth in the Declaration of Helsinki. The study protocol was reviewed and approved by an Ethics Committee. Written informed consent was obtained from all patients.
Details of biochemical analysis, lipoprotein fractionation and characterization, endogenous plasma CETP activity, free cholesterol efflux assays, in vitro and in vivo determination of selective uptake of HDL-CE, and statistical analysis are available in the supplemental Methods.
Results
The effects of CETP inhibition on plasma lipid and apolipoprotein levels and on HDL subfractions are presented in details in the supplemental Results.
Effects of CETP Inhibition on Cellular Free Cholesterol Efflux
To evaluate the impact of CETP inhibition on the capacity of whole plasma to mediate cellular free cholesterol efflux, we used 3 cellular models, each representative of a specific cholesterol efflux pathway 20 (see supplemental Results).
The capacity of isolated HDL2 and HDL3 subfractions to mediate cellular free cholesterol efflux via SR-BI, ABCG1, and ABCA1 pathways is shown in Figure 1 . HDL2 particles isolated from Type IIB dyslipidemic plasmas at baseline displayed an impaired capacity to mediate cholesterol efflux through both SR-BI (Ϫ32%; PϽ0.0001) and ABCG1 (Ϫ20%; PϽ0.02) pathways as compared to control subjects. However, torcetrapib-mediated inhibition of CETP significantly increased and restored the capacity of HDL2 particles from dyslipidemic patients to mediate free cholesterol efflux via both SR-BI (ϩ38%; PϽ0.003) and ABCG1 (ϩ35%; PϽ0.03) pathways as compared to baseline before drug therapy. By contrast, HDL3 particles isolated from Type IIB dyslipidemic plasmas displayed an impaired capacity to mediate cholesterol efflux through both SR-BI (Ϫ58%; PϽ0.0001) and ABCA1 (Ϫ47%; PϽ0.0001) pathways as compared to control subjects. Significantly, torcetrapib-mediated inhibition of CETP did not normalize the defective efflux capacities of HDL3 particles.
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Effects of CETP Inhibition on Cholesteryl Ester Transfer Rates
The impact of CETP inhibition on the capacity of HDL subfractions to act as donors of cholesteryl ester to CETP and apoB-lipoproteins in the indirect pathway of reverse cholesterol transport is presented in Table. Transfer rates of cholesteryl ester from HDL to apoB-lipoproteins in type IIB patients were significantly higher (ϩ36%; PϽ0.0001) as compared to normolipidemic subjects, reflecting an elevated endogenous plasma CETP activity in hyperlipidemic subjects. After atorvastatin treatment alone, the mean rate of cholesteryl ester transfer from HDL to apoB-lipoproteins was significantly reduced (Ϫ18%; PϽ0.001) in Type IIB patients. As expected, combination of torcetrapib with atorvastatin induced an additional significant reduction in total endogenous plasma CETP activity in Type IIB patients as compared to atorvastatin alone (Ϫ49%) and equally as compared to baseline (Ϫ60%). Interestingly, when individual donor HDL particle subfractions were considered, we observed that the HDL2 subfraction acted as the major CE donor in normolipidemic control subjects, accounting for 79% of total cholesteryl ester transferred from HDL. By contrast, in Type IIB patients, the CE transfer rate from HDL2 was significantly reduced (Ϫ29%; PϽ0.001), whereas that from HDL3 was considerably increased (3.8-fold) as compared to normolipidemic controls. When the total CE mass transferred from HDL was expressed as a function of plasma lipoprotein donor concentration, the capacity of each HDL subfraction to donate CE can be estimated. 21 Thus, in normolipidemic subjects, HDL2 particles displayed a 3-fold superior capacity to transfer CE in comparison with HDL3, whereas HDL2 and HDL3 subfractions in type IIB patients at baseline possessed an equivalent capacity to donate CE as a result of a 3.8-fold increase in the capacity of HDL3 from dyslipidemic patients to transfer CE as compared to those from control subjects. In Type IIB patients receiving atorvastatin alone, the CE transfer rate from HDL2 to apoB-lipoproteins was significantly reduced (Ϫ26%; PϽ0001) as compared to baseline, whereas that from HDL3 remained unchanged (Table) . Furthermore, the capacity of HDL2 subfractions from type IIB patients to transfer CE to apoB-lipoproteins was significantly lowered (Ϫ28%; PϽ0.001) by atorvastatin therapy as compared to baseline. Torcetrapib-mediated inhibition of CETP further reduced the CE transfer rate from HDL2 as compared to atorvastatin alone (Ϫ29%; PϽ0.02) such that it was 3-fold lower than that in control subjects; in addition, CE transfer from HDL3 was normalized (Ϫ58%; PϽ0.0001) only by combination torcetrapib/atorvastatin therapy. Moreover, CETP inhibition significantly lowered the capacity of HDL2 (Ϫ60%; PϽ0.0005) from type IIB patients to donate CE to atherogenic particles as compared to atorvastatin alone (2fold less) and baseline (3-fold less). By contrast, combination therapy reduced the CE transfer capacity of HDL3 to levels typical of control subjects.
Effects of CETP Inhibition on Selective CE-Uptake in the Liver
The effect of torcetrapib-mediated inhibition of CETP on the capacity of HDL particles to deliver cholesteryl esters to the liver was evaluated in vitro using hepatic cellular models of human origin (HepG2) and of murine origin (Fu5AH) ( Figure  2 ), and in vivo in C57Bl/6 mice ( Figure 3 ). In vitro, HDL particles isolated from the plasma of type IIB patients displayed a reduced capacity (PϽ0.05) to deliver CE to hepatic cells as compared to those isolated from the plasma of normolipidemic controls subjects (Ϫ25% and Ϫ21% in Fu5AH and HepG2 cells, respectively). By contrast, HDL particles isolated from type IIB patients treated with combination torcetrapib/atorvastatin therapy showed a significant elevation (1.7-fold; PϽ0003) in their capacity to deliver CE to hepatic cells as compared to those from patients at baseline.
Metabolic studies of radiolabeled HDL were performed in C57Bl/6 mice to evaluate the impact of CETP inhibition on HDL-CE uptake by the liver in vivo. Time course curves of plasma radioactivity decay of human labeled HDL-CE injected into mice revealed that HDL particles isolated from torcetrapib/atorvastatin-treated type IIB patients displayed an enhanced activity for hepatic uptake of CE as compared to HDL isolated from atorvastatin-treated or untreated patients ( Figure 3A) . Indeed, analysis of plasma radioactivity disappearance revealed that 30% of the radioactivity was cleared between 2 hours and 6 hours after injection of HDL particles from type IIB patients at baseline or after atorvastatin alone, whereas the disappearance of radioactivity attained 44% when HDL from type IIB torcetrapib/atorvastatin-treated patients were injected ( Figure 3B ). Tissue uptake of radioactive CE derived from HDL was significantly increased (ϩ52%; PϽ0.03) in the liver after injection of HDL particles isolated from type IIB patients receiving combination torcetrapib/atorvastatin as compared to those from the same patients before or after atorvastatin alone ( Figure 3C ). Thus, both our in vitro and in vivo observations are consistent in suggesting that HDL particles formed on torcetrapibmediated CETP inhibition are endowed with an enhanced capacity to mediate selective hepatic uptake of CE.
Discussion
The present studies have focused on the identification of structural and functional anomalies in the major HDL subfractions, ie, HDL2 and HDL3, in patients displaying a mixed dyslipidemic phenotype (Fredrickson Type IIB), and have tested the hypothesis that efficacious inhibition of the indirect reverse cholesterol transport pathway targeted to CETP would favor normalization of such structural and functional defects. Indeed, we have demonstrated that large cholesteryl ester-rich HDL2 particles in such dyslipidemic patients displaying subnormal HDL-cholesterol levels are defective in their capacity to mediate cholesterol efflux through both the SR-BI and ABCG1 pathways when compared to the corresponding subfraction in normolipidemic subjects on a per particle basis. Equally, the capacity of HDL particles to deliver CE to the liver by selective uptake both in vivo and in vitro is impaired in this atherogenic hyperlipidemia. By contrast, the HDL3 subfraction from Type IIB patients displayed a supranormal capacity to transfer CE to apoBlipoproteins through the action of CETP when evaluated by an assay dependent on the endogenous content of CE donor (HDL) and acceptor particles (VLDL, IDL, and LDL). Significantly, torcetrapib-mediated inhibition of CETP favored normalization of the major abnormal physicochemical properties of HDL particles in our dyslipidemic patients, including both the neutral lipid core ratio of CE/TG and biological functions. These functions include SR-BI-mediated cellular free cholesterol efflux, the capacity of HDL particles to mediate selective hepatic uptake of CE in vivo and in vitro, and the capacity of HDL3 particles to transfer CE to apoB-lipoproteins. 
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Treatment with a combination of torcetrapib/atorvastatin induced marked elevation in HDL2 levels; moreover, HDL2 particles on treatment were enriched in CE, phospholipids, and apoAI, but in contrast, depleted in triglycerides as compared to baseline and treatment with atorvastatin alone. Such modifications were consistent with torcetrapib-induced partial inhibition of plasma CETP activity. 18, 21 Inversely, CETP-mediated neutral lipid transfer from HDL to apoB lipoproteins is primarily associated with reduction in HDL particle size as well as with dissociation of apoAI from HDL. 22 As large HDL can efficiently efflux cellular cholesterol via the SR-BI pathway, 19 it was essential to evaluate whether such SR-BI-mediated cholesterol efflux might be enhanced after CETP inhibition. Indeed, large HDL2 particles generated under torcetrapib treatment displayed elevated capacity to mediate cellular cholesterol efflux via the SR-BI pathway in vitro. Moreover, and in agreement with earlier observations, 18 torcetrapib-mediated CETP inhibition enhanced the capacity of HDL2 particles to mediate cellular free cholesterol efflux via the ABCG1 pathway. It is relevant, however, that Yvan-Charvet et al 18 reported earlier that CETP inhibition by torcetrapib enhanced the ability of HDL to promote free cholesterol efflux via the ABCG1 pathway only at the highest dose (120 mg/d) of CETP inhibitor in moderate hypercholesterolemic subjects and that this dose was without effect on the SR-BI mediated efflux pathway. These apparently conflicting observations may, in all likelihood, result from differences in the subject populations between the two studies. Indeed, we presently report that HDL particles isolated from type IIB hyperlipidemic plasmas displayed an altered capacity to mediate cholesterol efflux via both SR-BI and ABCG1 pathways as compared to normolipidemic controls, and that such impaired capacity was essentially normalized on combination atorvastatin/torcetrapib therapy (see supplemental Discussion).
In human plasma, the major pathway for the return of HDL-CE to the liver occurs via apoB lipoproteins after CETP-mediated CE transfer. 23 However, it is significant that torcetrapib-mediated partial inhibition of CETP resulted in elevation in the capacity of HDL particles to deliver CE to the liver, thereby facilitating hepatic uptake of CE via the direct reverse cholesterol transport pathway. Thus, the degree of CETP inhibition might incrementally influence cholesterol flux through this pathway in Type IIB hyperlipidemia. The relationship of the content of apoE in HDL under conditions of low CETP activity remains controversial. Several studies have reported increased levels of apoE-rich HDL particles in CETP-deficient subjects. 24 -26 Partial CETP inhibition by torcetrapib in monotherapy induces elevation in apoE content in large HDL particles at the highest dose (120 mg/d), whereas the lower dose (60 mg/d) was without effect on HDL-apoE in moderate hypercholesterolemic subjects. 18 In the present study, plasma levels of apoE in type IIB patients were significantly decreased by 25% (PϽ0.0001) after atorvastatin alone as compared to baseline. No significant variation in plasma apoE levels was, however, detected between atorvastatin-treated patients and those receiving combination atorvastatin/torcetrapib therapy. As large HDL particles containing apoE represent a minor lipoprotein subspecies within the circulating apoAI-containing HDL particle pool, as atorvastatin therapy leads to upregulation of hepatic LDL receptors, it is likely that large apoE-enriched HDL particles generated after CETP inhibition by torcetrapib therapy were rapidly cleared from the circulation.
Our present observations on the impact of torcetrapibmediated CETP inhibition on key steps of the reverse cholesterol pathway allow us to propose an integrated mechanism of action of CETP inhibitors on cholesterol metabolism in patients displaying the Type IIB phenotype (Figure 4 ). In the normolipidemic state, plasma free cholesterol efflux from peripheral tissue occurs via specific ABC membrane transporters, ABCA1 and ABCG1, or via receptors such as SR-BI/CLA-1 ( Figure 4A ). Free cholesterol is taken up by lipid poor-ApoAI complexes, pre␤-HDL, or mature HDL particles according to the receptor/transporter involved. LCAT allows the transformation of lipid-poor pre␤-HDL to HDL3 and subsequently to HDL2, thereby generating large CE-enriched HDL2. CETP redistributes CE from HDL to apoB-lipoproteins. 3 In normolipidemic subjects, such CE transfer mainly involves HDL2 and LDL particles. 27 The final step of the RCT pathway represents the return of CE to the liver, via selective HDL-CE uptake involving SR-BI/CLA-1 or via uptake of LDL by specific hepatic LDL-receptors. By contrast, key steps of the reverse cholesterol transport pathway are altered in Type IIB hyperlipidemia as compared to the normolipidemic state ( Figure 4B) . Firstly, the capacity of HDL particles to mediate free cholesterol efflux from peripheral tissues with subsequent CE delivery to the liver is impaired in this dyslipidemic state. Thus, rates of CE transfer from HDL to apoB-lipoproteins are accelerated as a result of an increase in both plasma CETP level and circulating number of apoB-containing CE acceptor particles. 28 In contrast with normolipidemic subjects, type IIB patients are characterized by elevated rates of CE transfer from HDL3 to TRL particles which are the primary CE acceptors in this phenotype. 29 Such elevated CETP-mediated heterotransfer of neutral lipid between HDL and TRL contributes to reduction in HDL-C levels and favors the formation of TG-enriched HDL particles. Type IIB hyperlipidemia also involves an atherogenic lipid triad characterized by elevated circulating levels of TRL, including VLDL, VLDL remnants, and IDL, and a predominance of atherogenic small dense LDL particles. 30 This triad results in an imbalance attributable to an excess of cholesterol in atherogenic apoB lipoproteins relative to that in atheroprotective HDL, thereby favoring peripheral cholesterol deposition and enhanced atherogenesis. 31 HMG-CoA reductase inhibitors, such as atorvastatin, primarily act by inhibiting cellular biosynthesis of cholesterol in the liver ( Figure 4C ). The reduction of intracellular cholesterol content induces hepatic LDL receptor expression and as a direct consequence, enhances uptake of all apoB lipoproteins by the liver. 32 In this way, atorvastatin therapy decreases 
plasma levels of TRL and equally those of LDL subfractions including small dense LDL. 8, 33 In addition, atorvastatin attenuates CETP-mediated CE transfer from HDL to TRL, mainly as a result of reduced CE transfer rates from HDL2, whereas that from HDL3 is not affected and remains elevated. Such statin-mediated reduction in endogenous plasma CETP activity results in retention of CE in HDL with induction of an elevation in numbers of large HDL2 particles, thereby enhancing the capacity of whole plasma to promote cellular cholesterol efflux via the SR-BI/CLA-1 pathway. 33 By contrast, atorvastatin has no impact on the attenuated capacity of HDL particles from type IIB patients to mediate free cholesterol efflux from peripheral cells with subsequent CE delivery to the liver. Nonetheless, atorvastatin normalizes the quantitative and qualitative features of apoB lipoproteins in large part, but appears to lack impact on functionally defective HDL particles in Type IIB hyperlipidemia. Torcetrapibmediated inhibition of CETP, on a background of atorvastatin therapy, normalizes several features of the functionality of defective HDL particles and of intravascular HDL remodeling in this phenotype ( Figure 4D ). Elevation in plasma levels of large HDL2 particles is associated with normalization of core neutral lipid content (CE/TG ratio) of both HDL2 and HDL3 subspecies, with potential correction of apoAI conformation and thence their biological activities. 10, 11 Partial CETP inhibition enhances the capacity of HDL2 particles to mediate free cholesterol efflux from peripheral cells via both SR-BI/CLA-1 and ABCG1 pathways, whereas altered efflux capacities of HDL3 from type IIB patients are not corrected. Equally, CETP inhibition enhances the capacity of HDL particles to deliver CE to the liver for selective uptake. Critically, partial CETP inhibition reduces supranormal CE transfer rates from HDL3 to apoB lipoproteins and thus attenuates their potential atherogenicity by reducing their core CE content and cholesterol load. Clearly then, pharmacological inhibition of CETP, in association with statinmediated upregulation of hepatic LDL receptors, accelerates key steps of both the direct and indirect reverse cholesterol transport pathways, thereby maintaining efficient removal of cholesterol from peripheral tissues and the arterial wall with return to the liver.
Sources of Funding
We are indebted to Pfizer and to INSERM (Institut National de la Santé et de la Recherche Médicale) for generous support of these studies. G.C. was the recipient of a Research Fellowship from Fondation pour la Recherche Médicale (FRM).
